Camacho Raul C, Denny Joshua C, Pencek R Richard, Koyama Yoshiharu, Lacy D Brooks, James Freyja D, Wasserman David H
Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashille, TN 37232, USA.
Metabolism. 2004 Oct;53(10):1290-5. doi: 10.1016/j.metabol.2004.07.002.
The purpose of the present study was to assess whether physiological portal vein hyperinsulinemia stimulates gut glucose absorption in vivo. Chronically catheterized (femoral artery, portal vein, inferior vena cava, and proximal and distal duodenum) and instrumented (Doppler flow probe on portal vein) insulin (INS, 2 mU.kg(-1).min(-1), n = 6) or saline (SAL, n = 5) infused dogs were studied during basal (30 minutes) and experimental (90 minutes) periods. Arterial and portal vein plasma insulin were 3.3- and 3.2-fold higher, respectively, throughout the study in INS compared to SAL. An intraduodenal glucose infusion of 8 mg.kg(-1).min(-1) was initiated at t = 0 minutes. At t = 20 and 80 minutes, a bolus of 3-O-[3H]methylglucose (MG) and L-[14C]glucose (L-GLC) was injected intraduodenally. Phloridzin, an inhibitor of the Na+ -dependent glucose transporter (SGLT1), was infused from t = 60 to 90 minutes in the presence of a peripheral isoglycemic clamp. Net gut glucose output (NGGO) was 5.2 +/- 0.6 and 4.6 +/- 0.8 mg.kg(-1).min(-1) in INS and SAL, respectively, from t = 20 to 60 minutes. Transporter-mediated absorption was 87% +/- 2% of NGGO in both INS and SAL. Passive gut glucose absorption was 13% +/- 2% of NGGO in both INS and SAL. Phloridzin-induced inhibition of transporter-mediated absorption completely abolished passive absorption of L-GLC in both groups. This study shows that under physiological conditions, a portal vein insulin infusion that results in circulating hyperinsulinemia does not increase either transporter-mediated or passive absorption of an intraduodenal glucose load.
本研究的目的是评估生理性门静脉高胰岛素血症是否会在体内刺激肠道葡萄糖吸收。对长期插管(股动脉、门静脉、下腔静脉以及十二指肠近端和远端)并安装仪器(门静脉上的多普勒血流探头)的犬进行研究,这些犬持续输注胰岛素(INS,2 mU·kg⁻¹·min⁻¹,n = 6)或生理盐水(SAL,n = 5),研究分为基础期(30分钟)和实验期(90分钟)。在整个研究过程中,INS组的动脉和门静脉血浆胰岛素水平分别比SAL组高3.3倍和3.2倍。在t = 0分钟开始经十二指肠输注葡萄糖,剂量为8 mg·kg⁻¹·min⁻¹。在t = 20和80分钟时,经十二指肠注射一剂3 - O - [³H]甲基葡萄糖(MG)和L - [¹⁴C]葡萄糖(L - GLC)。在存在外周等血糖钳夹的情况下,从t = 60到90分钟输注钠依赖性葡萄糖转运体(SGLT1)抑制剂根皮苷。在t = 20到60分钟期间,INS组和SAL组的肠道葡萄糖净输出(NGGO)分别为5.2±0.6和4.6±0.8 mg·kg⁻¹·min⁻¹。在INS组和SAL组中,转运体介导的吸收均占NGGO的87%±2%。被动性肠道葡萄糖吸收在INS组和SAL组中均占NGGO的13%±2%。根皮苷诱导的转运体介导吸收的抑制完全消除了两组中L - GLC的被动吸收。本研究表明,在生理条件下,导致循环中高胰岛素血症的门静脉胰岛素输注不会增加十二指肠葡萄糖负荷的转运体介导吸收或被动吸收。